Turn Therapeutics
Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapies (lead candidate GX-03 for atopic dermatitis) and FDA-cleared wound care devices, all powered by its proprietary PermaFusion® drug delivery platform.
- Company typePublic
- Founded2013
- HeadquartersCalabasas, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Turn Therapeutics does
Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapeutics and FDA-cleared medical devices for dermatology, wound care, and infectious disease. The company is built on its proprietary PermaFusion® drug delivery platform, an oil-based formulation technology that enables water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers or adjuvants, allowing topical delivery of molecules that would normally require injection. The lead clinical asset is GX-03, a non-systemic therapy targeting IL-36α, IL-36γ, IL-31, and IL-4 for moderate-to-severe atopic dermatitis; Phase 2 interim data showed 92.6% of treated subjects achieving EASI-50 within 4 weeks and 70.4% achieving EASI-75, with no treatment-related serious adverse events. The company also markets three FDA 510(k)-cleared medical devices (Hexagen Wound Dressing, XEAL, and FLEX AM) that have collectively recorded over 200,000 human uses with zero reported adverse events.
Turn Therapeutics firmographics
Firmographics- Name
- Turn Therapeutics
- Legal name
- Global Health Solutions, Inc.
- Website
- https://turntherapeutics.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Turn Therapeutics is a clinical-stage biotechnology company developing first-in-class topical cytokine-modulating therapies (lead candidate GX-03 for atopic dermatitis) and FDA-cleared wound care devices, all powered by its proprietary PermaFusion® drug delivery platform.
- Ownership category
- akta.pro rank
Turn Therapeutics industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Dermatology Specialty Pharmaceuticals (HLAIACAL), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
Keywords
Where Turn Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Calabasas
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Turn Therapeutics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales & Licensing: Revenue generated through global supply, development, and license agreement with Medline for commercialization of products using PermaFusion platform. FDA-cleared medical devices including Hexagen Wound Dressing and XEAL Antimicrobial Oil Emulsion Dressing generate revenue through licensing and supply arrangements. MIMEDX partnership for FLEX AM includes $70M+ milestone potential.
- Future Drug Product Sales: Upon regulatory approval, GX-03 for atopic dermatitis and onychomycosis will be commercialized through traditional retail pharmacy channels. Moderate-to-severe eczema market growing at 15% CAGR, forecast to reach nearly $30B by 2031.
- Crowdfunding and Public Market Capital: Company conducted Regulation Crowdfunding campaigns through StartEngine enabling retail investor participation. Direct listing on Nasdaq (TTRX) in October 2025 provides ongoing capital market access.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Turn Therapeutics product offering
Product offeringCore offering
Turn Therapeutics develops first-in-class topical cytokine-modulating therapeutics powered by its proprietary PermaFusion® oil-based drug delivery platform for inflammatory skin diseases, with lead candidate GX-03 in Phase 2 trials for moderate-to-severe atopic dermatitis. The company also markets FDA-cleared antimicrobial medical devices (Hexagen Wound Dressing, XEAL, FLEX AM, AtopX) for wound care and dermatology through enterprise licensing partners Medline and MIMEDX. Commercial revenue is generated via licensing and supply arrangements, with future drug sales planned through retail pharmacy channels upon regulatory approval.
Product overview
Turn Therapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class topical therapeutics powered by its proprietary PermaFusion® drug delivery platform. The core product is GX-03, a non-systemic cytokine-modulating therapy targeting IL-36 and IL-31 for inflammatory skin diseases. The company also markets FDA-cleared medical devices including Hexagen Wound Dressing, XEAL, FLEX AM, and AtopX. An intranasal vaccine candidate is in development leveraging the same PermaFusion technology for enhanced stability.
Differentiator
Problem solved
Functional benefit
Brands
- PermaFusion: Proprietary drug delivery platform that enables water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers, adjuvants, or unnecessary additives.
- Hexagen
- XEAL
- FLEX AM
- AtopX
Products and services
- GX-03 First-in-class non-systemic topical cytokine-modulating therapy targeting IL-36α, IL-36γ, IL-31, and IL-4 for moderate-to-severe atopic dermatitis and onychomycosis. Currently in Phase 2 clinical trials with interim data showing 92.6% EASI-50 and 70.4% EASI-75 within 4 weeks.
- PermaFusion® Platform Proprietary oil-based drug delivery platform enabling water-soluble therapeutic agents to penetrate deeper tissue layers without emulsifiers or adjuvants. Underpins Turn's therapeutic pipeline and FDA-cleared medical devices, protected by 15+ patents.
- Hexagen Wound Dressing FDA-cleared antimicrobial oil emulsion wound dressing with petrolatum-based formulation. Has over 200,000 human uses with zero reported adverse events. Commercialized globally through Medline partnership.
- XEAL Antimicrobial Oil Emulsion Dressing
Quantifiable outcome
- 92.6% of GX-03-treated subjects achieved at least 50% reduction in eczema severity within 4 weeks (EASI-50)
- +5 more outcomes
Companies that use Turn Therapeutics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Turn Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Turn Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship, strategic and major.
- MedlineflagshipGlobal supply, development, and license agreement with Medline (largest provider of medical-surgical products) to develop, manufacture, and commercialize products using Turn's PermaFusion platform. Medline employs 43,000+ people and operates in over 100 countries. Expected to generate revenue beginning late 2026 in advanced wound care market.
- International AIDS Vaccine Initiative (IAVI)strategicPartnership to develop thermostable intranasal vaccine using IAVI's rVSV-MARV vector in Turn's proprietary oil-based delivery system. Validated 100% recovery of VSV after 24 and 72 hours in oil carrier at room temperature. Collaboration advancing multi-arm stability studies.
- MIMEDXmajorExclusive licensing of FLEX AM (Antimicrobial Collagen Powder) to MIMEDX for wound care applications. Partnership includes $70M+ milestone potential. MIMEDX focuses on regenerative medicine.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Turn Therapeutics competitors and assessment
Company assessmentDirect peers
- Arcutis Biotherapeutics: Direct competitor developing topical therapeutics for inflammatory skin diseases including atopic dermatitis (ZORYVE cream); both companies pursue topical alternatives to systemic biologics in the same dermatology space with similar regulatory and commercial pathways.
- Dermavant Sciences: Develops topical therapeutics for inflammatory skin diseases (VTAMA/tapinarof cream for psoriasis and atopic dermatitis); competes head-to-head with Turn's GX-03 in the topical non-steroidal dermatology category.
- Incyte Corporation: Markets Opzelura (ruxolitinib cream), a topical JAK inhibitor approved for atopic dermatitis; directly competes with GX-03 in the topical inflammatory skin disease market with established commercial infrastructure.
- MiMedx Group: Exclusive licensee of Turn's FLEX AM antimicrobial collagen powder and a peer in regenerative wound care; comparable business model focused on biologics for advanced wound management with similar distribution channels.
- Organogenesis Holdings: Commercial-stage regenerative medicine company selling wound care biologics (Apligraf, Dermagraft) into the same advanced wound care market where Turn's Hexagen, XEAL, and FLEX AM compete; closely comparable product portfolio and customer base.
Broad incumbents
- Regeneron Pharmaceuticals: Co-develops and commercializes Dupixent (dupilumab) with Sanofi, the dominant systemic biologic for moderate-to-severe atopic dermatitis; defines the standard-of-care that Turn's topical approach aims to differentiate from.
- AbbVie: Markets Rinvoq (upadacitinib), an oral JAK inhibitor approved for atopic dermatitis; broader immunology incumbent competing for the same moderate-to-severe patient population Turn targets.
- Galderma: Dermatology-focused pharmaceutical company developing nemolizumab (IL-31 inhibitor biologic) and other inflammatory skin disease therapeutics; overlaps with Turn's cytokine-targeting approach and shares the dermatology specialty channel.
Others
- Medline Industries: Largest privately-held manufacturer and distributor of medical-surgical products and Turn's global commercialization partner for PermaFusion-based products; relevant as channel partner and scale benchmark in advanced wound care.
Emerging players
- Castle Biosciences: Emerging dermatology-focused commercial-stage company with skin-inflammation and diagnostics pipeline; comparable in size and stage profile to Turn, also pursuing dermatology specialty markets with proprietary technologies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Turn Therapeutics social profiles
Digital presenceTurn Therapeutics compliance and trust
Trust signalCompliance1 record
Turn Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Turn Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Turn Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Turn Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Turn Therapeutics
What does Turn Therapeutics do?
Turn Therapeutics develops first-in-class topical cytokine-modulating therapeutics powered by its proprietary PermaFusion® oil-based drug delivery platform for inflammatory skin diseases, with lead candidate GX-03 in Phase 2 trials for moderate-to-severe atopic dermatitis. The company also markets FDA-cleared antimicrobial medical devices (Hexagen Wound Dressing, XEAL, FLEX AM, AtopX) for wound care and dermatology through enterprise licensing partners Medline and MIMEDX. Commercial revenue is generated via licensing and supply arrangements, with future drug sales planned through retail pharmacy channels upon regulatory approval.
Is Turn Therapeutics a public or private company?
Turn Therapeutics is a public company. It is classified as public and is currently operating.
When was Turn Therapeutics founded?
Turn Therapeutics was founded in 2013. It employs 1 to 10 people.
Where is Turn Therapeutics based?
Turn Therapeutics is headquartered in Calabasas, United States, in the North America region.
How does Turn Therapeutics make money?
Three revenue lines are on record. Medical Device Sales & Licensing is the primary driver. The others are future Drug Product Sales and crowdfunding and Public Market Capital.
Who are Turn Therapeutics's main competitors?
Direct peers on record are Arcutis Biotherapeutics, Dermavant Sciences, Incyte Corporation, MiMedx Group and Organogenesis Holdings. Broad incumbents are Regeneron Pharmaceuticals, AbbVie and Galderma. Medline Industries is listed as an others. Castle Biosciences is listed as an emerging player.
Does Turn Therapeutics have an API?
No public API is recorded for Turn Therapeutics.
What industry is Turn Therapeutics in?
Turn Therapeutics's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.